In PTC and melanoma, the upregulation of MET and ERBB3 expression level induced by BRAFi conferred BRAFi resistance to BRAFV600E mutant carcinomas, and inhibitors of MET and ERBB family could reserve the resistance to BRAFi effectively37-41. Here, EGFR is linked to melanoma.